RAD51 and acute myeloid leukemia: Seedhouse et al. reported no effect for the variant XRCC3 241Met gene alone in either de novo AML or therapy-related AML (t-AML) but demonstrated an increased risk of AML when both variants RAD51 135C and XRCC3 241Met alleles were present [31].